Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00009577-201505001-00015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Juxtaglomerular Cell Tumor With Cytohistological Correlation: A Case Report.
Diagn Cytopathol
February 2025
University of Virginia School of Medicine Inova Campus, Falls Church, Virginia, USA.
Juxtaglomerular cell tumors (JCT) are uncommon renin-secreting tumors of the kidney with cytologic findings of JCT rarely reported. We describe a case of JCT in a 37-year-old man with uncontrolled hypertension that was cured by removal of the tumor via partial nephrectomy. Cytology material was prepared by scraping of the freshly sectioned tumor mass and stained with Diff-Quik and Papanicolaou stains.
View Article and Find Full Text PDFUltrasonography-Guided Fine Needle Aspiration Cytology Versus Histopathology: Diagnostic Consistency in Salivary Gland Neoplasms.
Cureus
September 2024
Community and Family Medicine, All India Institute of Medical Sciences (AIIMS) Deoghar, Deoghar, IND.
Introduction Salivary gland lesions include a diverse range of histological types and biological behaviors, making accurate diagnosis and effective treatment challenging for specialists. Fine needle aspiration cytology (FNAC) plays a significant role in making preoperative diagnoses and further plans of surgery. In differentiating malignant from benign salivary gland tumors, the diagnostic accuracy of fine needle aspiration cytology (FNAC) is high.
View Article and Find Full Text PDFPitfalls in Diagnosis of Myoepithelial Carcinoma of Salivary Glands: A Study of 3 Cases with Cytologic-histologic Correlation and Molecular Analysis.
Head Neck Pathol
October 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
Context: Myoepithelial carcinoma (MECA) represents < 1% percent of salivary gland (SG) tumors with a mean age of 55 years. These tumors can arise de novo or in association with pre-existing pleomorphic Adenoma (PA). The cytologic features of MECA overlap with other SG neoplasms including the more common benign entities like PA and myoepithelioma and can pose a diagnostic challenge.
View Article and Find Full Text PDFCritical Appraisal of the 2017 Bethesda System for Reporting Thyroid Cytopathology with Cytohistological Concordance and Estimation of Risk of Malignancy - An Institutional Study.
Indian J Otolaryngol Head Neck Surg
October 2024
Department of Otorhinolaryngology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi, 110062 India.
Aim: Bethesda System for reporting thyroid cytopathology established in 2009 was updated for the first time in 2017. Since its introduction very few studies have been done on the utility of recently introduced "The 2017 Bethesda System for Reporting Thyroid Cytopathology" (TBSRTC II) and estimation of risk of malignancy in various categories.
Material And Methods: This was a prospective study done on thyroid lesions in which lesions were evaluated cytologically and classified according to TBSRTC II.
AICyte-alone capabilities as an independent screener for triaging cervical cytology using a 50% negative cutoff value.
Cancer Cytopathol
November 2024
Department of Pathology, Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Article Synopsis
- AICyte's study evaluated its potential to reduce workload in cervical cytology screening by implementing a 50% negative cutoff value across 163,848 cases collected from various hospitals in China.
- Results showed that 98.80% of cases marked as not needing further review by AICyte had negative original diagnoses, with high sensitivity and negative predictive values for identifying lesions.
- The findings suggest that using AICyte could streamline diagnostic processes and decrease the burden on pathologists by categorizing certain cases as negative without further review.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!